NCT06134830

Brief Summary

  1. 1.Determine the frequency of utilizing single and multiple doses of radioactive iodine (RAI) in treatment of differentiated thyroid cancer.
  2. 2.Asses the impact of various doses of radioactive iodine on the management of differentiated thyroid cancer.
  3. 3.Investigate the influence of thyroid cancer on the quality of life of affected patients.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Mar 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Mar 2024Jan 2027

First Submitted

Initial submission to the registry

November 13, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

February 6, 2024

Status Verified

February 1, 2024

Enrollment Period

2.8 years

First QC Date

November 13, 2023

Last Update Submit

February 3, 2024

Conditions

Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

  • The proportion of patients with differentiated thyroid cancer receiving a single dose of RAI.

    Proportion of differentiated thyroid cancer patients treated with single dose of RAI.

    2 Years

Secondary Outcomes (1)

  • Quality of life score of affected patients will be assessed through validated quality of life questionnaire (SF-36).

    2 Years

Interventions

RAIDRUG

Radioactive iodine

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with differentiated cancer thyroid treated at Assiut University Hospitals.

You may qualify if:

  • Patients with differentiated cancer thyroid either papillary or follicular underwent total thyroidectomy with or without lymph node dissection.
  • Available data of patients' records.

You may not qualify if:

  • Missed follow up data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, Luster M, Schlumberger M, Smit JW. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046. doi: 10.1530/ETJ-21-0046.

    PMID: 34981741BACKGROUND

  • Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. Eur Thyroid J. 2017 Jul;6(4):187-196. doi: 10.1159/000468927. Epub 2017 Mar 23.

    PMID: 28868259BACKGROUND

  • Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006 Jun;154(6):787-803. doi: 10.1530/eje.1.02158. No abstract available.

    PMID: 16728537BACKGROUND

  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.

    PMID: 26462967BACKGROUND

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Central Study Contacts

Hager Hamdy, Master

CONTACT

01159047417hagham669@gmail.com

Hoda Hassan

CONTACT

01001732757hodahassanessa@yahoo.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical outcome and quality of life in differentiated thyroid cancer patients treated with different doses of radioactive iodine.

Study Record Dates

First Submitted

November 13, 2023

First Posted

November 18, 2023

Study Start

March 1, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2027

Last Updated

February 6, 2024

Record last verified: 2024-02